Sponsor Symposia

NUTRICIA DINNER SYMPOSIUM

Modern MCI Care: Linking Cognitive Health, functional ageing and nutritional considerations

Join Dr Desmond Graham, Chief Medical Officer at Geriatric Care Australia,

and featuring a Q&A panel on proactive care with Dr Stephanie Daly & Caroline Gibson.

Spaces Limited. RSVP in the registration platform

Tuesday, 23rd June 2026

About the symposium:

Mild cognitive impairment (MCI) is increasingly recognised as a heterogeneous, potentially modifiable clinical state rather than a single pre-dementia pathway. In day-to-day practice, cognitive symptoms rarely occur in isolation: they intersect with frailty, sarcopenia, malnutrition and multimorbidity, driving functional decline, falls, hospitalisation, and loss of independence. This presentation provides a contemporary, practical framework for clinicians to assess and manage MCI through a “cognition–function–nutrition” lens.

We will review modern definitions and phenotypes of MCI, including how to differentiate neurodegenerative trajectories from reversible or contributory factors (medications, sleep, mood, sensory impairment, delirium vulnerability, and systemic illness). We will then explore the bidirectional links between cognitive impairment and frailty biology, shared inflammation, hormonal changes, inactivity, and social determinants, and how sarcopenia and poor nutritional status amplify cognitive and functional risk.

Attendees will be guided through an integrated assessment approach that pairs brief cognitive screening with functional evaluation (ADLs/IADLs, gait speed, balance), frailty and sarcopenia screening, and structured nutritional assessment (weight loss history, protein/energy intake, swallowing/dental issues). Evidence-informed management strategies will be discussed, emphasising multidisciplinary care and targeted interventions: resistance and balance training, optimisation of protein and energy intake, addressing vitamin and micronutrient deficits where relevant, medication rationalisation, and goal-oriented care planning.

Using case vignettes and actionable tools, the session will highlight referral pathways, monitoring metrics, and communication strategies to support patients and families, including telehealth-enabled follow-up and links with community and aged care services. The aim is to shift practice from “diagnose and watch” to proactive, measurable care that preserves function and supports healthy ageing.

GSK LUNCH SYMPOSIUM

Impact of Viral Infections on Comorbid Geriatric Patients: Your Role in Prevention

Join A/Prof Adam Nelson and Professor Peter Gonski

on the importance of effective vaccine conversation with patients and how to embed vaccinations into specialist workflow

Spaces Limited. RSVP in the registration platform

Wednesday, 24th June 2026 | 1:00 PM

About the symposium:

This interactive session brings together renowned Australian experts to discuss the burden of viral infections on patients with cardiovascular disease and to provide practical tips regarding preventive health conversations with patients.

  • Gain Expert Insights: Participate in a session chaired by Professor Peter Gonski, featuring discussions with a renowned cardiology expert, Associate Professor Adam Nelson, on impact of RSV and shingles on cardiovascular patients.

  • Disease Burden: Professor Peter Gonski will share insights into the burden of vaccine-preventable disease in his patients, and the implications for clinical outcomes with a patient case study.

  • Prevention Strategies: Listen from Professor Peter Gonski and Associate Professor Adam Nelson on the importance of preventing viral diseases, including RSV and shingles, in patients with cardiovascular conditions.

  • Patient Conversations: Hear from Professor Peter Gonski and Associate Professor Adam Nelson on the importance of effective vaccine conversation with patients and how to embed vaccinations into specialist workflow

About GSK:

We are a focused biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade with ambitious plans for growth and continuing to make GSK a company where everyone can thrive.

We prevent and treat disease with specialty medicines, vaccines and general medicines. We focus on the science of the immune system and advanced technologies, investing in four core therapeutic areas (respiratory, immunology and inflammation; oncology; HIV; and infectious diseases) to impact health at scale.

We operate responsibly for all our stakeholders by prioritising Innovation, Performance and Trust. For more information visit au.gsk.com.

AbbVie LUNCH SYMPOSIUM

Join Dr Michele De Sciscio MBBS FRACP

A Focus on Advanced Parkinson’s Disease

Spaces Limited. RSVP in the registration platform

Thursday, 25th June 2026 | 1:30 PM

About the symposium:

This session delivers a thorough exploration of device-aided therapies (DATs) for advanced Parkinson’s disease, designed to provide balanced, practical insights for clinicians. Starting with an overview of existing DAT options—including DUODOPA, , DBS and Apomorphine . The session outlines the spectrum of available therapeutic strategies, highlighting their mechanisms, advantages, and clinical considerations.

A session will introduce of VYALEV 9 VYALEV (Foslevodopa/Foscarbidopa), including its novel mechanism of action and the innovative VYAFUSER delivery device, to ensure participants are equipped with up-to-date information on emerging solutions. The session also emphasizes real-world patient selection, providing practical guidance on identifying candidates for referral. Discussion will address key factors impacting referral decisions, such as symptom profiles, prior treatments, patient preferences, and care goals.

About Dr Michele De Sciscio:

Dr Michele De Sciscio is a General Neurologist committed to providing the best care possible with a patient centred, empathetic and evidence-based approach.  He completed his medical degree at Flinders University in 2012 and subsequent Adult Neurology Training at the Royal Adelaide Hospital.

He holds a fellowship in Movement Disorders, with specific expertise in the management of neurodegenerative disorders, such as Parkinson’s Disease, and the use of botulinum therapy for the treatment of a range of neurological conditions.

Dr De Sciscio is also involved in clinical research, leading multiple clinical trials currently investigating emerging treatment options for Parkinson’s Disease.